ENTO - Wutah pendapatan taun lumaku enterothera.com

Entero Therapeutics, Inc. (ENTO) develops enzyme-based treatments to combat celiac disease, establishing a comprehensive therapy system for digestive pathologies. However, the lack of recurring revenue and the costs associated with clinical trials are creating a liquidity deficit. The relative change in trailing twelve-month revenue compared to the same period last year confirms these data, with the current level standing at 0.00, reflecting the reaction of commercial volumes to external market shifts.
Entero Therapeutics - rincian analitis lan metrik utama (ENTO)

Entero Therapeutics, Inc. (ENTO) focuses on developing innovative therapies for patients with gastrointestinal pathologies, making the annual trend of sales revenue over four quarters a key indicator of its asset commercialization. This metric measures the market consensus of the value of goods sold over a rolling year on a daily basis, allowing investors to strip away accounting distortions and objectively assess the real demand for the company's drugs.